Imran Ahmad
Corporate Officer/Principal at MASCO CORPORATION
Net worth: 500 269 $ as of 2024-04-29
Active connections
| Name | Gender | Age | Linked companies | Collaboration |
|---|---|---|---|---|
| Keith Allman | M | 61 | 26 years | |
| Lisa Payne | F | 65 | 18 years | |
| Christopher O'Herlihy | M | 60 | 11 years | |
| Aine Denari | M | 51 | 2 years | |
| Sandeep Reddy | M | 53 | 1 years | |
| Kenneth Cole | M | 58 | 20 years | |
| Marie Ffolkes | F | 52 | 7 years | |
| John Plant | M | 70 | 12 years | |
| Jonathon Nudi | M | 53 | 1 years | |
| Mark Alexander | M | 59 | 10 years | |
| Jai Shah | M | 57 | 21 years | |
| Charles Stevens | M | 64 | 6 years | |
| Donald Parfet | M | 71 | 12 years | |
| Renee Straber | F | 53 | 29 years | |
| Binish Hasmukh Chudgar | M | 61 |
Astron Research Ltd. (United Kingdom)
 Astron Research Ltd. (United Kingdom) Miscellaneous Commercial ServicesCommercial Services Astron Research Ltd. provides contract research and regulatory support services to pharmaceutical companies. Its services include dossier development, formulation and analytical research, regulatory affairs, and quality assurance. The company was founded in 2001 and is established in London, the United Kingdom. | - |
| Urmish Hasmukh Chudgar | M | 64 |
Astron Research Ltd. (United Kingdom)
Astron Research Ltd. (United Kingdom) Miscellaneous Commercial ServicesCommercial Services Astron Research Ltd. provides contract research and regulatory support services to pharmaceutical companies. Its services include dossier development, formulation and analytical research, regulatory affairs, and quality assurance. The company was founded in 2001 and is established in London, the United Kingdom. | - |
| Nimish Chudgar | M | - |
Astron Research Ltd. (United Kingdom)
Astron Research Ltd. (United Kingdom) Miscellaneous Commercial ServicesCommercial Services Astron Research Ltd. provides contract research and regulatory support services to pharmaceutical companies. Its services include dossier development, formulation and analytical research, regulatory affairs, and quality assurance. The company was founded in 2001 and is established in London, the United Kingdom. | - |
| Kirti Bansidhar Maheshwari | M | - |
Astron Research Ltd. (United Kingdom)
Astron Research Ltd. (United Kingdom) Miscellaneous Commercial ServicesCommercial Services Astron Research Ltd. provides contract research and regulatory support services to pharmaceutical companies. Its services include dossier development, formulation and analytical research, regulatory affairs, and quality assurance. The company was founded in 2001 and is established in London, the United Kingdom. | - |
| Richard Westenberg | M | 50 | 1 years | |
| Renee Benedict | F | - | 24 years | |
| Robin Zondervan | F | 44 | 2 years | |
| Rick Marshall | M | - | - | |
| Susan Sabo | F | - | 18 years |
Connections Chart
Multi-company connection
Former connections
| Name | Gender | Age | Linked companies | Collaboration |
|---|---|---|---|---|
| J. Losh | M | 78 | 18 years | |
| Lawrence Kenyon | M | 58 |
NeoPharm, Inc.
 NeoPharm, Inc. BiotechnologyHealth Technology NeoPharm, Inc. engages in the research, development, and commercialization of drugs for the treatment of various cancers and other diseases. The company has built its drug development program around two proprietary technology platforms, a tumor-targeting toxin platform which includes development for a new indication of Pulmonary Fibrosis, and a novel NeoLipid liposomal drug delivery system. It has advanced five drug product candidates in various stages of clinical and pre clinical development for the treatment of cancer and one drug product candidate in pre-clinical development for treatment of interstitial pulmonary fibrosis and asthma. NeoPharm was founded in May 15, 1900and is headquartered in Lake Bluff, IL. | 6 years |
| Guillermo A. Herrera | M | 70 |
NeoPharm, Inc.
NeoPharm, Inc. BiotechnologyHealth Technology NeoPharm, Inc. engages in the research, development, and commercialization of drugs for the treatment of various cancers and other diseases. The company has built its drug development program around two proprietary technology platforms, a tumor-targeting toxin platform which includes development for a new indication of Pulmonary Fibrosis, and a novel NeoLipid liposomal drug delivery system. It has advanced five drug product candidates in various stages of clinical and pre clinical development for the treatment of cancer and one drug product candidate in pre-clinical development for treatment of interstitial pulmonary fibrosis and asthma. NeoPharm was founded in May 15, 1900and is headquartered in Lake Bluff, IL. | 2 years |
| Reginald Turner | M | 64 | 8 years | |
| John Sznewajs | M | 56 | 27 years | |
| Mary van Lokeren | F | 77 | 21 years | |
| Richard Manoogian | M | 87 | - | |
| Joseph B. Gross | M | - | 3 years | |
| Richard O’Reagan | M | - | 8 years | |
| Shahid Ali | M | - |
NeoPharm, Inc.
NeoPharm, Inc. BiotechnologyHealth Technology NeoPharm, Inc. engages in the research, development, and commercialization of drugs for the treatment of various cancers and other diseases. The company has built its drug development program around two proprietary technology platforms, a tumor-targeting toxin platform which includes development for a new indication of Pulmonary Fibrosis, and a novel NeoLipid liposomal drug delivery system. It has advanced five drug product candidates in various stages of clinical and pre clinical development for the treatment of cancer and one drug product candidate in pre-clinical development for treatment of interstitial pulmonary fibrosis and asthma. NeoPharm was founded in May 15, 1900and is headquartered in Lake Bluff, IL. | 10 years |
| Amit Bhargava | M | 60 | 5 years | |
| Kirk Rosemark | M | - |
NeoPharm, Inc.
NeoPharm, Inc. BiotechnologyHealth Technology NeoPharm, Inc. engages in the research, development, and commercialization of drugs for the treatment of various cancers and other diseases. The company has built its drug development program around two proprietary technology platforms, a tumor-targeting toxin platform which includes development for a new indication of Pulmonary Fibrosis, and a novel NeoLipid liposomal drug delivery system. It has advanced five drug product candidates in various stages of clinical and pre clinical development for the treatment of cancer and one drug product candidate in pre-clinical development for treatment of interstitial pulmonary fibrosis and asthma. NeoPharm was founded in May 15, 1900and is headquartered in Lake Bluff, IL. | 11 years |
| Frank C. Becker | M | 88 |
NeoPharm, Inc.
NeoPharm, Inc. BiotechnologyHealth Technology NeoPharm, Inc. engages in the research, development, and commercialization of drugs for the treatment of various cancers and other diseases. The company has built its drug development program around two proprietary technology platforms, a tumor-targeting toxin platform which includes development for a new indication of Pulmonary Fibrosis, and a novel NeoLipid liposomal drug delivery system. It has advanced five drug product candidates in various stages of clinical and pre clinical development for the treatment of cancer and one drug product candidate in pre-clinical development for treatment of interstitial pulmonary fibrosis and asthma. NeoPharm was founded in May 15, 1900and is headquartered in Lake Bluff, IL. | 7 years |
| Jeffrey Sherman | M | 69 |
NeoPharm, Inc.
NeoPharm, Inc. BiotechnologyHealth Technology NeoPharm, Inc. engages in the research, development, and commercialization of drugs for the treatment of various cancers and other diseases. The company has built its drug development program around two proprietary technology platforms, a tumor-targeting toxin platform which includes development for a new indication of Pulmonary Fibrosis, and a novel NeoLipid liposomal drug delivery system. It has advanced five drug product candidates in various stages of clinical and pre clinical development for the treatment of cancer and one drug product candidate in pre-clinical development for treatment of interstitial pulmonary fibrosis and asthma. NeoPharm was founded in May 15, 1900and is headquartered in Lake Bluff, IL. | 7 years |
| Paul Freiman | M | 89 |
NeoPharm, Inc.
NeoPharm, Inc. BiotechnologyHealth Technology NeoPharm, Inc. engages in the research, development, and commercialization of drugs for the treatment of various cancers and other diseases. The company has built its drug development program around two proprietary technology platforms, a tumor-targeting toxin platform which includes development for a new indication of Pulmonary Fibrosis, and a novel NeoLipid liposomal drug delivery system. It has advanced five drug product candidates in various stages of clinical and pre clinical development for the treatment of cancer and one drug product candidate in pre-clinical development for treatment of interstitial pulmonary fibrosis and asthma. NeoPharm was founded in May 15, 1900and is headquartered in Lake Bluff, IL. | 7 years |
| Gregory P. Young | M | 70 |
NeoPharm, Inc.
NeoPharm, Inc. BiotechnologyHealth Technology NeoPharm, Inc. engages in the research, development, and commercialization of drugs for the treatment of various cancers and other diseases. The company has built its drug development program around two proprietary technology platforms, a tumor-targeting toxin platform which includes development for a new indication of Pulmonary Fibrosis, and a novel NeoLipid liposomal drug delivery system. It has advanced five drug product candidates in various stages of clinical and pre clinical development for the treatment of cancer and one drug product candidate in pre-clinical development for treatment of interstitial pulmonary fibrosis and asthma. NeoPharm was founded in May 15, 1900and is headquartered in Lake Bluff, IL. | 1 years |
| Christopher K. Kastner | M | - | - | |
| Timothy Walbert | M | 57 |
NeoPharm, Inc.
NeoPharm, Inc. BiotechnologyHealth Technology NeoPharm, Inc. engages in the research, development, and commercialization of drugs for the treatment of various cancers and other diseases. The company has built its drug development program around two proprietary technology platforms, a tumor-targeting toxin platform which includes development for a new indication of Pulmonary Fibrosis, and a novel NeoLipid liposomal drug delivery system. It has advanced five drug product candidates in various stages of clinical and pre clinical development for the treatment of cancer and one drug product candidate in pre-clinical development for treatment of interstitial pulmonary fibrosis and asthma. NeoPharm was founded in May 15, 1900and is headquartered in Lake Bluff, IL. | 1 years |
| Steven B. Binion | M | 71 |
NeoPharm, Inc.
NeoPharm, Inc. BiotechnologyHealth Technology NeoPharm, Inc. engages in the research, development, and commercialization of drugs for the treatment of various cancers and other diseases. The company has built its drug development program around two proprietary technology platforms, a tumor-targeting toxin platform which includes development for a new indication of Pulmonary Fibrosis, and a novel NeoLipid liposomal drug delivery system. It has advanced five drug product candidates in various stages of clinical and pre clinical development for the treatment of cancer and one drug product candidate in pre-clinical development for treatment of interstitial pulmonary fibrosis and asthma. NeoPharm was founded in May 15, 1900and is headquartered in Lake Bluff, IL. | - |
| Bernard A. Fox | M | - |
NeoPharm, Inc.
NeoPharm, Inc. BiotechnologyHealth Technology NeoPharm, Inc. engages in the research, development, and commercialization of drugs for the treatment of various cancers and other diseases. The company has built its drug development program around two proprietary technology platforms, a tumor-targeting toxin platform which includes development for a new indication of Pulmonary Fibrosis, and a novel NeoLipid liposomal drug delivery system. It has advanced five drug product candidates in various stages of clinical and pre clinical development for the treatment of cancer and one drug product candidate in pre-clinical development for treatment of interstitial pulmonary fibrosis and asthma. NeoPharm was founded in May 15, 1900and is headquartered in Lake Bluff, IL. | 7 years |
| John Palmer Lindow | M | 60 | 22 years |
Statistics
| Country | Connections | % of total |
|---|---|---|
| United States | 40 | 90.91% |
| United Kingdom | 4 | 9.09% |
Age of Connections
Active
Past
Male
Female
Members of the board
Executives
Origin of connections
- Stock Market
- Insiders
- Imran Ahmad
- Personal Network